What is Precision Biosystems?
Precision Biosystems operates at the intersection of biotechnology and automated hardware, providing essential tools for western blot processing and nucleic acid analysis. The company's flagship product, the BlotCycler, addresses a critical pain point in laboratory workflows by automating immunodetection, thereby eliminating the variability inherent in manual protocols. Complementing this, the Qsep100 capillary gel electrophoresis system offers high-resolution DNA and RNA separation, catering to research facilities that prioritize reproducibility and cost-efficiency. By streamlining these complex analytical processes, Precision Biosystems has established itself as a vital partner for laboratories aiming to optimize throughput without compromising data integrity. The firm's focus on low-maintenance, high-performance instrumentation aligns with the broader industry shift toward standardized, automated research environments.
How much funding has Precision Biosystems raised?
Precision Biosystems has raised a total of $30K across 1 funding round:
Debt
$30K
Debt (2021): $30K with participation from PPP
Key Investors in Precision Biosystems
PPP
Public-Private Partnership
What's next for Precision Biosystems?
With the recent infusion of capital, Precision Biosystems is poised to transition into a more aggressive scaling phase. The strategic roadmap likely involves expanding its global distribution network and investing in R&D to further refine its automated electrophoresis and blotting platforms. As the company matures through its Series B/C lifecycle, the focus will shift toward capturing a larger share of the clinical and academic research market. By leveraging its current technological advantage, the firm is expected to enhance its operational footprint, potentially introducing next-generation iterations of its core product line to meet the evolving demands of high-throughput genomic and proteomic research facilities. This financial milestone provides the necessary runway to solidify its competitive standing against legacy instrumentation providers.
See full Precision Biosystems company page
